Neoplasms

Digestive System Diseases

All Conditions

Rare Diseases

Gastrointestinal Stromal Tumors

Antineoplastic Agents

All Drugs and Chemicals

Crenolanib

Placebo

Jean-Yves Blay, MD

Margaret von Mehren, MD

This is a multicenter, randomized, double-blinded, placebo-controlled, trial of oral crenolanib versus oral placebo in combination with best supportive care in subjects with advanced or metastatic GIST with a D842V mutation in the PDGFRA gene. Approximately 120 subjects will be randomized in a 2:1 ratio to receive either crenolanib 100 mg or matching placebo orally (PO) 3 times daily (TID) in combination with best supportive care.

Randomized Trial of Crenolanib in Subjects With D842V Mutated GIST

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of Crenolanib in Subjects With Advanced or Metastatic Gastrointestinal Stromal Tumors With a D842V Mutation in the PDGFRA Gene

Centre Leon Berard

Fox Chase Cancer Center

Arog Pharmaceuticals, Inc.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Randomized Trial of Crenolanib in Subjects With D842V Mutated GIST	NCT02847429	GIST With D842V...	Crenolanib Placebo	18 Years -	Arog Pharmaceuticals, Inc.
Randomized Trial of Crenolanib in Subjects With D842V Mutated GIST	NCT02847429	GIST With D842V...	Crenolanib Placebo	18 Years -	Arog Pharmaceuticals, Inc.

Spots Global Cancer Trial Database for gist with d842v mutated pdgfra gene